Browsing Centre for Experimental Cancer Medicine by Title

Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

Choueiri, T; Escudier, B; Powles, T; Mainwaring, P; Rini, B; Donskov, F; Hammers, H; Hutson, T; Roth, B; Peltola, K (2015-09)

The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration

Munkley, J; McClurg, UL; Livermore, KE; Ehrmann, I; Knight, B; Mccullagh, P; Mcgrath, J; Crundwell, M; Harries, LW; Leung, HY (2017-07-12)

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Mayrhofer, M; De Laere, B; Whitington, T; Van Oyen, P; Ghysel, C; Ampe, J; Ost, P; Demey, W; Hoekx, L; Schrijvers, D (BioMed Central, 2018-11-21)

BACKGROUND: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential ...

Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations

Manchanda, R; Burnell, M; Loggenberg, K; Desai, R; Wardle, J; Sanderson, SC; Gessler, S; Side, L; Balogun, N; Kumar, A (2016-07)

Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities

Chuang, L; Berek, J; Randall, T; McCormack, M; Schmeler, K; Manchanda, R; Rebbeck, T; Jeng, CJ; Pyle, D; Quinn, M (2018-06)

Comment on 'Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'

Shamash, J; Sarker, S-J (2014-01-07)

Commentary on changing the risk threshold for surgical prevention of ovarian cancer.

Manchanda, R; Legood, R; Antoniou, AC; Pearce, L; Menon, U (2018-04)

A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm

MANCHANDA, R; GABA, F (Wiley, 2019-03-04)

Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population

Blyuss, O; Burnell, M; Ryan, A; Gentry-Maharaj, A; Marino, IP; Kalsi, J; Manchanda, R; Timms, JF; Parmar, M; Skates, SJ (2018-10-01)

CONSERVATIVE TREATMENT FOR FERTILITY SPARING IN YOUNG WOMEN WITH ENDOMETRIAL CANCER AND ATYPICAL HYPERPLASIA. RESULTS FROM A ON GOING PROSPECTIVE SINGLE CENTRE STUDY

La Russa, M; Biliatis, I; Brockbank, E; Faruki, A; Lawrence, A; Manchanda, R; Singh, N; Jeyarajah, A (2016)

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women

Patel, S; Legood, R; Evans, DG; Turnbull, C; Antoniou, AC; Menon, U; Jacobs, I; Manchanda, R (2018-04)

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry

Manchanda, R; Patel, S; Antoniou, AC; Levy-Lahad, E; Turnbull, C; Evans, G; Hopper, JL; Macinnis, RJ; Menon, U; Jacobs, I (2017-11)

Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History-Based Testing

Manchanda, R; Legood, R; Burnell, M; McGuire, A; Raikou, M; Loggenberg, K; Wardle, J; Sanderson, S; Gessler, S; Side, L (2015-01)

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

Manchanda, R; Patel, S; Gordeev, VS; Antoniou, AC; Smith, S; Lee, A; Hopper, JL; MacInnis, RJ; Turnbull, C; Ramus, SJ (2018-07)

Cost-effectiveness of systematic population based screening for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 gene mutations in unselected general population women

Manchanda, R; Gordeev, V; Antoniou, A; Smith, S; Lee, A; Hopper, J; Macinnis, R; Paul, P; Simon, G; Susan, R (2016-10)

COVID-19 and the impact on gynecologic cancer care

Manchanda, R; Oxley, S; Ghaem-Maghami, S; Sundar, S

Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population

Manchanda, R; Blyuss, O; Gaba, F; Gordeev, VS; Jacobs, C; Burnell, M; Gan, C; Taylor, R; Turnbull, C; Legood, R (2018-08)

Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.

Manchanda, R; Legood, R; Pearce, L; Menon, U (2015-12)

OBJECTIVE: To define risk thresholds for cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) for ovarian cancer (OC) prevention in low/intermediate risk postmenopausal women. METHODS: A decision-analytic model ...

DETECTION OF NON-OVARIAN CANCERS ON PHASE 2 OF THE UK FAMILIAL OVARIAN CANCER SCREENING STUDY (UKFOCSS)

Philpott, S; Rizzuto, I; Fraser, L; Manchanda, R; Hadwin, R; Burnell, M; Mackay, S; Skates, S; Menon, U; Jacobs, I (2013-10)

Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy

Manchanda, R; Silvanto, A; Abdelraheim, A; Burnell, M; Johnson, M; Saridogan, E; Rosenthal, AN; Brunell, C; Aslam, N; Vashisht, A (2012-06)